AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $46.38.

A number of analysts have commented on ANAB shares. SVB Leerink started coverage on AnaptysBio in a report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 price objective for the company. JPMorgan Chase & Co. decreased their price objective on AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, April 1st. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of AnaptysBio in a report on Friday, May 10th. Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. Finally, Wells Fargo & Company began coverage on AnaptysBio in a report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 target price for the company.

AnaptysBio Stock Performance

ANAB stock opened at $24.22 on Thursday. The stock’s 50 day simple moving average is $23.65 and its 200 day simple moving average is $23.05. The company has a market cap of $661.69 million, a P/E ratio of -3.94 and a beta of -0.33. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $27.50.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.64) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.10). The company had revenue of $7.18 million for the quarter, compared to the consensus estimate of $4.55 million. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%. Equities analysts predict that AnaptysBio will post -6.04 earnings per share for the current year.

Insider Activity at AnaptysBio

In other AnaptysBio news, Director Hollings Renton sold 1,950 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total transaction of $45,162.00. Following the sale, the director now owns 1,950 shares in the company, valued at $45,162. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Dennis Mulroy sold 1,500 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total value of $35,580.00. Following the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,866.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Hollings Renton sold 1,950 shares of the stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $23.16, for a total value of $45,162.00. Following the completion of the transaction, the director now directly owns 1,950 shares in the company, valued at approximately $45,162. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,400 shares of company stock worth $125,924. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC purchased a new position in AnaptysBio during the 1st quarter valued at about $38,000. China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares during the period. Quest Partners LLC purchased a new position in AnaptysBio during the 4th quarter valued at about $119,000. SG Americas Securities LLC purchased a new position in AnaptysBio during the 4th quarter valued at about $126,000. Finally, Virtu Financial LLC purchased a new position in AnaptysBio during the 1st quarter valued at about $222,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.